Professional Summary

Professional Overview

Christina Ansted is a seasoned biopharmaceutical executive with over 20 years of experience in the industry. As the Senior Managing Partner at RCP Venture Capital and the Founder and CEO of Rapid Commercialization Partners, she leverages her deep expertise in commercial strategy, global marketing, and business development to drive growth and innovation in the life sciences sector.

Experience Summary

Current Roles

Senior Managing Partner, RCP Venture Capital (2024-01-01 to Present)

Responsible for overseeing the investment strategy, portfolio management, and value creation initiatives for the venture capital firm

Actively involved in sourcing, evaluating, and managing investments in promising early-stage biotech and pharmaceutical companies

Serves as a strategic advisor to portfolio companies, leveraging her extensive industry knowledge and network to support their commercial and operational success

Advisory Board Member, Cila Therapeutics (2023-06-01 to Present)

Provides strategic guidance and industry insights to the leadership team of this emerging biopharmaceutical company

Advises on commercial planning, market access, and global expansion strategies to support the development and launch of the company's pipeline assets

Founder and Chief Executive Officer, Rapid Commercialization Partners (2020-09-01 to Present)

Established and leads this boutique consulting firm that specializes in helping biotech and pharmaceutical companies develop and execute successful commercialization strategies

Oversees a team of industry experts who provide strategic advisory services, market access solutions, and go-to-market planning to support clients' product launches and growth initiatives

Career Progression

Prior to her current roles, Christina held various leadership positions in the biopharmaceutical industry, including:

Executive Director, Global Shared Medical Services at PTC Therapeutics, Inc. (2018-08-01 to 2020-02-01)

Senior Director, Global Marketing Gene Therapy at Agilis Biotherapeutics (Acquired by PTC Therapeutics in July 2018) (2018-01-01 to 2018-07-01)

Director, Global HPP Marketing and Director, Global LAL-D Medical Marketing at Alexion Pharmaceuticals, Inc. (2015-12-01 to 2017-10-01)

Associate Director and Senior Manager, Global Medical Marketing at Alexion Pharmaceuticals, Inc. (2012-04-01 to 2015-12-01)

Throughout her career, Christina has demonstrated a strong track record of driving commercial success, leading cross-functional teams, and navigating complex regulatory and market environments.

Academic Background

Christina holds a Master of Science degree in Pharmacology from the University of Massachusetts Medical School and a Bachelor of Science degree in Biology from the University of Connecticut.

Areas of Expertise

Commercial strategy and planning

Global marketing and brand management

Market access and reimbursement

Business development and partnership management

Rare disease and specialty pharmaceutical markets

Venture capital and investment strategy

Professional Impact

Played a pivotal role in the successful launches of several rare disease and gene therapy products, driving patient access and adoption

Guided the growth and expansion of Rapid Commercialization Partners, establishing the firm as a trusted partner for biopharmaceutical companies seeking to optimize their commercial operations

Serves as a thought leader and industry expert, frequently speaking at prominent life sciences conferences and contributing to industry publications

Conclusion

With her extensive industry experience, deep domain expertise, and proven track record of driving commercial success, Christina Ansted is poised to continue making a significant impact in the biopharmaceutical sector. As she navigates her current roles, she remains focused on leveraging her strategic insights and collaborative approach to support the growth and innovation of the life sciences ecosystem.